Search

Your search keyword '"multiple myeloma"' showing total 954 results

Search Constraints

Start Over You searched for: Descriptor "multiple myeloma" Remove constraint Descriptor: "multiple myeloma" Journal frontiers in oncology Remove constraint Journal: frontiers in oncology
954 results on '"multiple myeloma"'

Search Results

1. The role of nutrition and gut microbiome in the progression of multiple myeloma and its precursor disease.

2. Association of CTLA-4 polymorphisms with hematologic malignancy susceptibility: a meta-analysis.

3. Large-scale genome-wide association studies reveal the genetic causal etiology between ankylosing spondylitis and risk of leukemia and lymphocytic malignancies.

4. Chimeric antigen receptor T-cells: a review on current status and future directions for relapsed/refractory multiple myeloma.

5. Case report: DKRd regimen in the treatment of newly diagnosed POEMS syndrome and literature review.

6. Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years.

7. Obstacles to global implementation of CAR T cell therapy in myeloma and lymphoma.

8. Advancements in microenvironment-based therapies: transforming the landscape of multiple myeloma treatment.

9. Venetoclax in the treatment of secondary plasma cell leukemia with translocation t(11;14): a case report and literature review.

10. Liposomes have a direct effect on multiple myeloma: a Mendelian randomization study.

11. Risk score constructed with neutrophil extracellular traps-related genes predicts prognosis and immune microenvironment in multiple myeloma.

12. Case report: An uncommon presentation of extramedullary plasmacytoma without a concurrent diagnosis of multiple myeloma.

13. Allogeneic stem cell transplantation in multiple myeloma: is there still a place?

14. Mechanisms and management of CAR T toxicity.

15. Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

16. The role of nutrition and gut microbiome in the progression of multiple myeloma and its precursor disease

17. Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma.

18. Activated interferon response, from DNA damage in multiple myeloma cells contributes to the chemotherapeutic effects of anthracyclines.

19. A comparative analysis of transcriptomics of newly diagnosed multiple myeloma: exploring drug repurposing.

20. Outcomes of percutaneous vertebroplasty in multiple myeloma: a tertiary neurosciences experience with long-term follow-up.

21. Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives.

22. Targeted therapy for multiple myeloma: an overview on CD138-based strategies.

23. Clinical efficacy and safety of combined anti-BCMA and anti-CD19 CAR-T cell therapy for relapsed/refractory multiple myeloma: a systematic review and meta-analysis.

24. Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy.

25. Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma.

26. Prognostic significance of β2-microglobulin decline index in multiple myeloma.

27. A retrotransposon-derived DNA zip code internalizes myeloma cells through Clathrin-Rab5a-mediated endocytosis.

28. Venetoclax in the treatment of secondary plasma cell leukemia with translocation t(11;14): a case report and literature review

29. Case report: An uncommon presentation of extramedullary plasmacytoma without a concurrent diagnosis of multiple myeloma

30. Allogeneic stem cell transplantation in multiple myeloma: is there still a place?

31. Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review.

32. On-demand plerixafor added to high-dose cyclophosphamide and pegylated recombinant human granulocyte colonystimulating factor in the mobilization of patients with multiple myeloma: a treatment with high effectiveness, convenient, and affordable cost.

33. Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma.

34. Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival.

35. Patient-reported symptoms and diagnostic journey in Multiple Myeloma.

36. Beyond BCMA: the next wave of CAR T cell therapy in multiple myeloma

37. Editorial: Reviews in hematologic malignancies: 2023

38. A comparative analysis of transcriptomics of newly diagnosed multiple myeloma: exploring drug repurposing

39. Outcomes of percutaneous vertebroplasty in multiple myeloma: a tertiary neurosciences experience with long-term follow-up

40. Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives

42. Targeted therapy for multiple myeloma: an overview on CD138-based strategies

43. Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy

44. Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma

45. Editorial: Reviews in hematologic malignancies: 2023.

46. On-demand plerixafor added to high-dose cyclophosphamide and pegylated recombinant human granulocyte colony-stimulating factor in the mobilization of patients with multiple myeloma: a treatment with high effectiveness, convenient, and affordable cost

47. The complex nature of lncRNA-mediated chromatin dynamics in multiple myeloma

48. Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study

49. Combined inhibition of Wee1 and Chk1 as a therapeutic strategy in multiple myeloma

50. Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment.

Catalog

Books, media, physical & digital resources